With reference to Regulation 30(11) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’) regarding a news item appearing in ‘https://www.cnbctv18.com/’dated April 23, 2026 captioned ‘Dr. Reddy's Laboratories still awaiting approval for a major near-term trigger, sources say’. In this connection, Dr. Reddy’s Laboratories has informed that the above captioned news item headline is correct, as the Company has not yet received approval (‘Notice of Compliance’) for its Semaglutide Injection from Health Canada. Further it has informed that as part of the regulatory review process, the Company has received the ‘Drug Identification Numbers (DINs)’ for Semaglutide Injection from Health Canada on April 22, 2026. The company continue to engage constructively with the regulatory authority and remain committed to bringing the product to the Canadian market upon approval. In compliance with Regulation 30 of the SEBI Listing Regulations, the Company makes prompt disclosures, as and when any event or information is considered material or warrants such disclosure under the said Regulations. The company has informed that at this stage there is no material event/ information that requires disclosure under Regulation 30 of the SEBI Listing Regulations.

The above information is a part of company’s filings submitted to BSE.